Cascade Chemistry begins $14m manufacturing facility expansion
pharmafile | February 19, 2021 | News story | Medical Communications | Cascade Chemistry, manufacturing
Cascade Chemistry, a leading pharmaceutical contract development and manufacturing organisation, has initiated the $14 million construction of new facilities to increase the company’s capacity to manufacture APIs (active pharmaceutical ingredients) under cGMP (current Good Manufacturing Practices standards and procedures).
The company’s new facilities, expected to be operational in the first quarter of next year, will ultimately increase the company’s floor space almost three-fold, and significantly add to its cGMP manufacturing capacity and scale. The expansion also includes 2,200 square feet of new analytical labs, a robust quality system, and additional office space.
The 28,000-square-foot building currently under construction will initially include five suites for Phase I and Phase II cGMP manufacturing, with flow hydrogenation and reactors up to 400 litres. Additional capacity for API Phase III and commercial scale cGMP manufacturing up to 1,000 litres will be added in 2022, while a second building of 7,000 square feet is reserved for future expansion.
Dr Jeremiah Marsden, President of Cascade Chemistry, said: “This $14 million expansion reflects our growing success as a reliable, experienced, and flexible outsourcing partner with exceptional chemistry problem-solving expertise.
“Our customers are increasingly requesting our assistance in producing APIs for their clinical trials, and demand has outstripped our cGMP manufacturing capacity. We were fortunate to acquire two suitable buildings just 10 minutes from our current facility, and construction of new cGMP manufacturing suites that will greatly increase our clinical trial API production capacity is now underway.”
Dr Marsden added: “We ultimately will expand into the second new building to build further cGMP capacity for commercial-stage low-volume, high-value pharmaceuticals. We are grateful for the support from our customers that is driving this expansion, as well as our employees’ dedication to excellence and their creativity and hard work that make it all possible.”
Darcy Jimenez
Related Content
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
AbbVie invests $223m in Singapore manufacturing site
AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing …
